- Stocks
- Pharma & Healthcare
- Morepen Laboratories
Morepen Laboratories share price
NSE: MOREPENLABPharma & HealthcareDrug Manufacturers - Specialty & Generic
Morepen Laboratories at a glance
Morepen Laboratories (NSE: MOREPENLAB) closed at ₹125.70 on 30 Sep 2026. With a market capitalisation of ₹6,888 Cr, it ranks 669th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 72.7× trailing earnings, against a return on equity of 7.6% in FY26. Over the past year the share price has risen 141.6%. Its 52-week range is ₹33.05 (30 Mar 2026) to ₹128.10 (30 Sep 2026); the last close is 1.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹570 Cr (+34.1% year on year) and net profit ₹56 Cr (+393.9%), on a consolidated basis. Promoters held 35.65% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹6,888 CrRank 669 on NSE
- P/E (trailing)
- 72.7×
- Price to book
- 1.49×FY26
- EPS (TTM)
- ₹2.56to Q1 FY27
- ROE
- 7.6%FY26
- ROCE
- 7.6%FY26
- Debt to equity
- 0.16FY26
- Net profit margin
- 5.3%FY26
- Book value / share
- ₹22.75FY26
- 52-week high
- ₹128.1030 Sep 2026
- 52-week low
- ₹33.0530 Mar 2026
- 1-year return
- +141.6%
- RSI (14-day)
- 66.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +5.63% | +2.6% | +17.1% | +111.3% | +141.6% |
Morepen Laboratories quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹438 Cr | ₹453 Cr | ₹466 Cr | ₹425 Cr | ₹412 Cr | ₹484 Cr | ₹485 Cr | ₹570 Cr |
| Revenue YoY | +3.8% | +1.9% | +10.1% | −6.6% | −6.0% | +6.9% | +4.1% | +34.1% |
| Net profit | ₹35 Cr | ₹27 Cr | ₹20 Cr | ₹11 Cr | ₹41 Cr | ₹28 Cr | ₹16 Cr | ₹56 Cr |
| Net profit YoY | +63.9% | −16.6% | −29.3% | −68.5% | +17.8% | +3.0% | −22.7% | +393.9% |
| Net margin | 8.0% | 5.9% | 4.4% | 2.7% | 10.0% | 5.7% | 3.2% | 9.9% |
| EPS | ₹0.65 | ₹0.49 | ₹0.35 | ₹0.20 | ₹0.75 | ₹0.50 | ₹0.28 | ₹1.03 |
Morepen Laboratories financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,188 Cr | ₹1,547 Cr | ₹1,418 Cr | ₹1,690 Cr | ₹1,812 Cr | — |
| Operating profit | ₹99 Cr | ₹127 Cr | ₹56 Cr | ₹135 Cr | ₹155 Cr | — |
| Net profit | ₹97 Cr | ₹102 Cr | ₹39 Cr | ₹97 Cr | ₹118 Cr | — |
| EPS (₹) | ₹2.00 | ₹2.00 | ₹1.00 | ₹2.00 | ₹2.00 | — |
| Cash from operations | ₹51 Cr | −₹58 Cr | −₹91 Cr | ₹73 Cr | ₹32 Cr | — |
| Total debt | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹3 Cr | ₹26 Cr | ₹134 Cr |
| Shareholders' equity | ₹425 Cr | ₹579 Cr | ₹753 Cr | ₹847 Cr | ₹1,156 Cr | ₹1,246 Cr |
Morepen Laboratories shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 35.65% | 35.65% | 35.65% | 35.65% | 35.65% | 35.65% |
| Foreign institutions | 1.94% | 1.72% | 1.62% | 1.62% | 1.58% | 1.46% |
| Domestic institutions | 1.67% | 1.51% | 1.50% | 1.25% | 1.25% | 1.28% |
| Non-institutions | 60.72% | 61.11% | 61.21% | 61.46% | 61.50% | 61.59% |
Morepen Laboratories vs peers
The listed Pharma & Healthcare companies nearest to Morepen Laboratories by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| THYROCAREThyrocare Technologies | ₹470.65 | +3.44% | +11.6% | ₹7,491 Cr | 46.2 | — |
| MOREPENLABMorepen Laboratories | ₹125.70 | +5.63% | +141.6% | ₹6,888 Cr | 72.7 | — |
| SUPRIYASupriya Lifescience | ₹848.80 | −0.02% | +19.4% | ₹6,831 Cr | 32.7 | — |
| BLISSGVSBliss GVS Pharma | ₹638.00 | +2.42% | +319.4% | ₹6,766 Cr | 53.1 | — |
| SANOFISanofi India | ₹2,845.00 | +0.53% | −40.0% | ₹6,552 Cr | 21.2 | — |
| ENTEROEntero Healthcare Solutions | ₹1,504.20 | −0.19% | +36.0% | ₹6,547 Cr | 57.1 | — |
| KOVAIKovai Medical Center & Hospital | ₹5,738.00 | −2.24% | +190.4% | ₹6,279 Cr | 25.7 | — |
Ask anything about Morepen Laboratories
Pivot answers on the live chart with evidence you can check, and tests strategies against MOREPENLAB's own history. Try: “Why has MOREPENLAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on MOREPENLAB over five years” · “Compare MOREPENLAB with THYROCARE on margins and valuation”
Frequently asked questions about Morepen Laboratories
What is the share price of Morepen Laboratories today?
Morepen Laboratories (NSE: MOREPENLAB) last closed at ₹125.70 on 30 Sep 2026. Its 52-week high is ₹128.10 and its 52-week low is ₹33.05.
What is the market cap of Morepen Laboratories?
Morepen Laboratories' market capitalisation is ₹6,888 Cr (₹6,888 Cr) at the 22 Oct 2026 close, ranking 669th among the NSE companies Pivot tracks.
What is the P/E ratio of Morepen Laboratories?
Morepen Laboratories trades at a trailing P/E of 72.7. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.2.
What is the ROE and ROCE of Morepen Laboratories?
Return on equity was 7.6% in FY26 and return on capital employed was 7.6% in FY26 (consolidated figures).
Is Morepen Laboratories a debt-free company?
No. Morepen Laboratories' debt-to-equity ratio was 0.16 in FY26, with total debt of ₹134 Cr.
What were Morepen Laboratories' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Morepen Laboratories reported revenue of ₹570 Cr, +34.1% year on year, and net profit of ₹56 Cr, +393.9% year on year.
How has Morepen Laboratories stock performed over the last year?
Morepen Laboratories' share price has risen 141.6% over the past year, +111.3% over three months and +17.1% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Morepen Laboratories?
As of 30 Jun 2026: promoters 35.65%, foreign institutions 1.46%, domestic institutions 1.28%, non-institutions 61.59%.
Who are Morepen Laboratories' competitors?
The listed Pharma & Healthcare companies closest to Morepen Laboratories by market cap are Thyrocare Technologies, Supriya Lifescience, Bliss GVS Pharma, Sanofi India, Entero Healthcare Solutions and Kovai Medical Center & Hospital.
Is Morepen Laboratories a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Morepen Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MOREPENLAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 30 Sep 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with M · all NSE stocks · this page as text